We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
Read MoreHide Full Article
Key Takeaways
Asceniv revenues rose 28% in Q1 2026, supported by strong demand from complex PIDD patients.
ADMA cut 2026 guidance as IG pricing pressure and competition weighed on near-term growth.
ADMA shares have lost 54.8% YTD as earnings estimates for 2026 and 2027 moved lower.
ADMA Biologics (ADMA - Free Report) develops and commercializes plasma-derived biologics used to treat immune deficiencies and help prevent certain infectious diseases.
The company currently generates revenues from three FDA-approved products: Bivigam, an intravenous immune globulin (IVIG) therapy for primary humoral immunodeficiency; Asceniv, indicated for primary immunodeficiency disease (PIDD); and Nabi-HB, which provides enhanced immunity against hepatitis B infection.
Increased competition, elevated channel inventories and aggressive pricing activity in standard immunoglobulin (IG) products created temporary pressure on top-line performance in the first quarter, particularly for Bivigam, whose sales declined 54% year over year.
On the other hand, Asceniv, its lead product, continues to maintain momentum. Asceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.
Asceniv remains a key growth driver for ADMA Biologics, with first-quarter 2026 revenues rising 28% year over year and demand trends continuing to strengthen. April demand levels indicate that second-quarter direct sales are tracking in line with the strong first-quarter performance, suggesting that momentum is being driven by underlying patient utilization rather than temporary inventory fluctuations.
The product’s differentiated positioning as a later-line therapy for highly complex and treatment-refractory immunodeficient patients provides ADMA Biologics with a meaningful competitive advantage. Because Asceniv serves a niche population with significant unmet need, demand has remained resilient even as the broader immunoglobulin market faces increasing competitive and pricing pressures.
While management continues to see strong underlying demand for Asceniv, the company lowered its 2026 guidance to reflect intensifying competitive pressures within the IG market. This suggests that near-term revenue growth could face headwinds despite healthy product utilization trends.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. Grifols’s primary plasma products include immunoglobulin (IG), Factor VIII, Alpha 1 (A1PI), and albumin. The company also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX, and plasma thromboplastin component.
Grifols has a strong presence across key segments of the plasma derivatives industry, including A1PI, IG, and albumin, supported by its leading position in plasma collection centers and robust fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
ADMA shares have plunged 54.8% year to date compared with the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. ADMA’s shares currently trade at 3.22X forward sales, lower than its mean of 3.72X but higher than the industry’s 2.05X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved south to 84 cents from 96 in the past 60 days, while that for 2027 EPS has declined to $1.05 from $1.38 in the same time frame.
View the Zacks #1 Rank List
Image: Bigstock
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
Key Takeaways
ADMA Biologics (ADMA - Free Report) develops and commercializes plasma-derived biologics used to treat immune deficiencies and help prevent certain infectious diseases.
The company currently generates revenues from three FDA-approved products: Bivigam, an intravenous immune globulin (IVIG) therapy for primary humoral immunodeficiency; Asceniv, indicated for primary immunodeficiency disease (PIDD); and Nabi-HB, which provides enhanced immunity against hepatitis B infection.
Increased competition, elevated channel inventories and aggressive pricing activity in standard immunoglobulin (IG) products created temporary pressure on top-line performance in the first quarter, particularly for Bivigam, whose sales declined 54% year over year.
On the other hand, Asceniv, its lead product, continues to maintain momentum. Asceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.
Asceniv remains a key growth driver for ADMA Biologics, with first-quarter 2026 revenues rising 28% year over year and demand trends continuing to strengthen. April demand levels indicate that second-quarter direct sales are tracking in line with the strong first-quarter performance, suggesting that momentum is being driven by underlying patient utilization rather than temporary inventory fluctuations.
The product’s differentiated positioning as a later-line therapy for highly complex and treatment-refractory immunodeficient patients provides ADMA Biologics with a meaningful competitive advantage. Because Asceniv serves a niche population with significant unmet need, demand has remained resilient even as the broader immunoglobulin market faces increasing competitive and pricing pressures.
While management continues to see strong underlying demand for Asceniv, the company lowered its 2026 guidance to reflect intensifying competitive pressures within the IG market. This suggests that near-term revenue growth could face headwinds despite healthy product utilization trends.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. Grifols’s primary plasma products include immunoglobulin (IG), Factor VIII, Alpha 1 (A1PI), and albumin. The company also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX, and plasma thromboplastin component.
Grifols has a strong presence across key segments of the plasma derivatives industry, including A1PI, IG, and albumin, supported by its leading position in plasma collection centers and robust fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
ADMA shares have plunged 54.8% year to date compared with the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. ADMA’s shares currently trade at 3.22X forward sales, lower than its mean of 3.72X but higher than the industry’s 2.05X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved south to 84 cents from 96 in the past 60 days, while that for 2027 EPS has declined to $1.05 from $1.38 in the same time frame.
Image Source: Zacks Investment Research
ADMA currently has a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.